Online inquiry

IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4560MR)

This product GTTS-WQ4560MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CXCR4 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001008540.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7852
UniProt ID P61073
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4560MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3561MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ2692MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ9961MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ1999MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ7399MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ3037MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ6787MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ7174MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW